News in movers and shakers

Australian Life Scientist brings you the latest in appointments and postings from the world of life science and biotechnology.

CBio (ASX:CBZ) has promoted board member Dr Ralph Craven to the post of chairman. Craven joined the board of the Brisbane-headquartered drug development company last month as a non-executive director. Non-executive director Helen Cameron, who was also appointed in November, has meanwhile been named interim managing director.

Research Australia, the non-profit health research alliance, has appointed Dr Anna Lavelle to its 18-member board. Lavelle, who has been CEO of industry body AusBiotech since 2005, will represent the biotechnology sector in board decisions. Research Australia is led by CEO Elizabeth Foley, and chaired by Dr Christine Bennett, dean of the school of medicine at Sydney University of Nortre Dame.

Hatchtech has tapped 27-year pharmaceutical industry veteran Timothy Waugh to be its new CEO. Waugh will lead Hatchtech through late-stage clinical development of its flagship DeOvo topical treatment for human head lice. He will be based out of New Jersey, USA, and will also join the company's board.

Allied Healthcare Group (ASX:AHZ) has chosen Bob Atwill to lead up the company's tissue engineering and regenerative medicine division, Celxel. Atwill has over 30 years' experience in the pharmaceutical, biotechnology and healthcare sectors, including as CEO of Clinical Cell Culture (now Avita Medical (ASX:AVH). Celxel was formerly part of Allied Medical, which merged with bioMD to create the Allied Healthcare Group six months ago.

Dr Leonard Post has joined the board of Viralytics (ASX:VLA) as a non-executive director. Post is currently CSO of BioMartin Pharmaceuticals, and has held positions with a number of other large pharmaceutical companies including Onyx Pharmaceuticals. Viralyrics specialises in developing oncolytic virotherapeutic treatments for cancers including late stage melanoma.